keyword
MENU ▼
Read by QxMD icon Read
search

Leukemia, multiple myeloma

keyword
https://www.readbyqxmd.com/read/29671785/activation-of-er-stress-dependent-mir-216b-has-a-critical-role-in-salvia-miltiorrhiza-ethanol-extract-induced-apoptosis-in-u266-and-u937-cells
#1
Changmin Kim, Hyo-Sook Song, Hojung Park, Bonglee Kim
Although Salvia miltiorrhiza has been reported to have anti-cancer mechanisms, such as caspase activation, cell cycle arrest, an anti-angiogenesis effect, and Bcl-2 family regulation, its underlying mechanism of endoplasmic reticulum (ER) stress-mediated apoptosis has never been demonstrated. Thus, in this current study, ER stress-related apoptosis via miR-216b of the ethanol extract of Salvia miltiorrhiza (SM) is elucidated for the first time. SM treatment inhibited the viability of U266 and U937 cells in a concentration-dependent manner...
April 19, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29667176/pre-diagnostic-blood-immune-markers-incidence-and-progression-of-b-cell-lymphoma-and-multiple-myeloma-univariate-and-functionally-informed-multivariate-analyses
#2
Roel Vermeulen, Fatemeh Saberi Hosnijeh, Barbara Bodinier, Lützen Portengen, Benoît Liquet, Javiera Garrido-Manriquez, Henk Lokhorst, Ingvar A Bergdahl, Soterios A Kyrtopoulos, Ann-Sofie Johansson, Panagiotis Georgiadis, Beatrice Melin, Domenico Palli, Vittorio Krogh, Salvatore Panico, Carlotta Sacerdote, Rosario Tumino, Paolo Vineis, Raphaële Castagné, Marc Chadeau-Hyam
Recent prospective studies have shown that dysregulation of the immune system may precede the development of B-cell lymphomas (BCL) in immunocompetent individuals. However, to date, the studies were restricted to a few immune markers, which were considered separately. Using a nested case-control study within two European prospective cohorts, we measured plasma levels of 28 immune markers in samples collected a median of 6 years prior to diagnosis (range, 2.01-15.97) in 268 incident cases of BCL (including multiple myeloma) and matched controls...
April 18, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29665944/-current-status-and-challenges-of-car-t-immunotherapy-in-hematologic-malignancies-review
#3
Xin Cheng, Ya-Jie Wang, Shuai Feng, Ya-Yun Wu, Tong-Hua Yang, Xun Lai
The chimeric antigen receptor (CAR) T cell therapy has gradually became a new trend in the treatment of refractory and relapsed hematologic malignancies by developing for 30 years. With the exciting development of genetic engineering, CAR-T technology has subjected to 4 generations of innovation. Structure of CAR-T started from a single signal molecule to 2 or more than 2 co-stimulatory molecules, and then coding the CAR gene or promoter. CAR-T can specifically recognize tumor antigens, and does not be restricted by major histocompatibility complex (MHC), thus making a breakthrough in clinical treatment...
April 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29665938/-research-and-applications-progress-of-lenalidomide-in-relapsed-refractory-blood-system-diseases-review
#4
Wen-Jing Fan, Zhi-Qiao Fan, Tao Wu, Hai Bai
Lenalidomide, a novel immunomodulatory agent, is a kind of thalidomide derivatives, which shows a good efficacy and safety for hematological system diseases. This review is aimed to evaluate the efficacy and safety of lenalidomide in treatment of patients with multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, classical Hodgkin's lymphoma and POEMS syndrome at their replased or refractory state. At the same time, this review focuses on the newest clinical research and the latest application progress of lenalidomide for relapsed or refractory hematological system diseases...
April 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29664669/primary-nonsecretory-plasma-cell-leukemia-with-multiple-chromosomal-abnormalities-a-case-report
#5
Satoshi Nakayama, Tomohiro Oda, Shinya Minabe, Yukiharu Bamba, Haruko Ukawa, Rika Sato, Masaki Kawabata, Toshikatsu Horiuchi, Junichi Watanabe, Fumihiko Kimura, Hideyuki Shimazaki, Sho Ogata, Kuniaki Nakanishi
Primary nonsecretory plasma cell leukemia (PCL) is an extremely rare type of multiple myeloma. Here, we report a case of nonsecretory PCL with no previous history of multiple myeloma. The case exhibited extremely low levels of serum immunoglobulin and light chain, no detectable serum M-protein or free light chain restriction, no urine BJP, and no cytoplasmic light chain expression in flow cytometry. In fluorescence in situ hybridization, tumor cells exhibited fusion genes for IgH/BCL1 and IgH/cMyc, disappearance of the p53 signal, and a split signal for IgK(2p11), but no split signal for IgL (22q11)...
January 1, 2018: Archives of Iranian Medicine
https://www.readbyqxmd.com/read/29661776/targeting-the-leukemia-antigen-pr1-with-immunotherapy-for-the-treatment-of-multiple-myeloma
#6
Gheath Alatrash, Alexander A Perakis, Celine Kerros, Haley L Peters, Pariya Sukhumalchandra, Mao Zhang, Haroon Jakher, Madhushree Zope, Rebecca S Patenia, Anna Sergeeva, Shuhua Yi, Ken H Young, Anne V Philips, Amanda C Herrmann, Haven R Garber, Na Qiao, Jinsheng Weng, Lisa S St John, Sijie Lu, Karen Clise-Dwyer, Elizabeth A Mittendorf, Qing Ma, Jeffrey J Molldrem
PURPOSE: PR1 is a human leukocyte antigen (HLA)-A2 nonameric peptide derived from neutrophil elastase (NE) and proteinase 3 (P3). We have previously shown that PR1 is cross-presented by solid tumors, leukemia, and antigen presenting cells, including B cells. We have also shown that cross-presentation of PR1 by solid tumors renders them susceptible to killing by PR1-targeting immunotherapies. Since multiple myeloma (MM) is derived from B cells, we investigated whether MM is also capable of PR1 cross-presentation and subsequently capable of being targeted using PR1 immunotherapies...
April 16, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29655962/novel-targets-and-technologies-for-car-t-cells-in-multiple-myeloma-and-acute-myeloid-leukemia
#7
EDITORIAL
Sabrina Prommersberger, Hardikkumar Jetani, Sophia Danhof, Razieh Monjezi, Thomas Nerreter, Julia Beckmann, Herrmann Einsele, Michael Hudecek
No abstract text is available yet for this article.
April 11, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29655704/a-library-of-phosphoproteomic-and-chromatin-signatures-for-characterizing-cellular-responses-to-drug-perturbations
#8
Lev Litichevskiy, Ryan Peckner, Jennifer G Abelin, Jacob K Asiedu, Amanda L Creech, John F Davis, Desiree Davison, Caitlin M Dunning, Jarrett D Egertson, Shawn Egri, Joshua Gould, Tak Ko, Sarah A Johnson, David L Lahr, Daniel Lam, Zihan Liu, Nicholas J Lyons, Xiaodong Lu, Brendan X MacLean, Alison E Mungenast, Adam Officer, Ted E Natoli, Malvina Papanastasiou, Jinal Patel, Vagisha Sharma, Courtney Toder, Andrew A Tubelli, Jennie Z Young, Steven A Carr, Todd R Golub, Aravind Subramanian, Michael J MacCoss, Li-Huei Tsai, Jacob D Jaffe
Although the value of proteomics has been demonstrated, cost and scale are typically prohibitive, and gene expression profiling remains dominant for characterizing cellular responses to perturbations. However, high-throughput sentinel assays provide an opportunity for proteomics to contribute at a meaningful scale. We present a systematic library resource (90 drugs × 6 cell lines) of proteomic signatures that measure changes in the reduced-representation phosphoproteome (P100) and changes in epigenetic marks on histones (GCP)...
April 10, 2018: Cell Systems
https://www.readbyqxmd.com/read/29644723/a-french-observational-study-describing-the-use-of-human-polyvalent-immunoglobulins-in-hematological-malignancy-associated-secondary-immunodeficiency
#9
Omar Benbrahim, Jean-François Viallard, Sylvain Choquet, Bruno Royer, Frédéric Bauduer, Olivier Decaux, Jean-Charles Crave, Yann Fardini, Pierre Clerson, Vincent Levy
OBJECTIVE: To describe the characteristics of patients suffering from secondary immunodeficiencies (SID) associated with hematological malignancies (HM), who started immunoglobulins replacement therapy (IgRT), physicians' expectations regarding IgRT and IgRT modalities. METHODS: Non-interventional, prospective French cross-sectional study. RESULTS: The analysis included 231 patients (66±12 years old) suffering from multiple myeloma (MM) (N=64), chronic lymphoid leukemia (CLL) (N=84), aggressive non-Hodgkin B-cell lymphoma (aNHL) (N=32), indolent NHL (N=39), acute leukemia (N=6), Hodgkin disease (N=6)...
April 12, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29622867/autologous-stem-cell-transplantation-for-multiple-myeloma-single-centre-experience-from-north-india
#10
Pankaj Malhotra, Uday Yanamandra, Alka Khadwal, Gaurav Prakash, Deepesh Lad, Arjun D Law, Harshit Khurana, M U S Sachdeva, Praveen Bose, Reena Das, Neelam Varma, Subhash Varma
Autologous stem cell transplantation (ASCT) is considered as standard of care in patients with multiple myeloma (MM) patients aged 65 years or younger. We analyzed data of 94 patients of plasma cell dyscrasias who underwent 95 autologous transplants at our institute from October 2003 to Aug 2016. Other than 76 patients of newly diagnosed multiple myeloma, we also transplanted two patients of POEMS syndrome, two patients of plasma cell leukemia, three patients of concurrent light chain deposition disease, three patients of multifocal plasmacytomas, and eight patients of isolated light chain myeloma...
April 2018: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/29616908/glioblastoma-multiforme-in-a-patient-with-multiple-myeloma-a-case-report-and-literature-review
#11
Christine A Moore, Moayed Ibrahim, Aaysha Kapila, Kailash Bajaj
INTRODUCTION: Lenalidomide is an immunomodulatory drug approved by the US Food and Drug Administration in 2006 for the treatment of multiple myeloma. In 2012, the Food and Drug Administration issued a statement warning physicians of the increased risk with lenalidomide treatment of the following secondary primary malignancies: Acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma. The statement did not mention glioblastoma multiforme, a Grade 4 astrocytoma, or other high-grade astrocytomas that have been reported on rare occasions in the setting of multiple myeloma...
March 30, 2018: Permanente Journal
https://www.readbyqxmd.com/read/29616647/epidemiology-of-malignant-hemopathies-recorded-in-hospitals-in-cameroon
#12
P T Moueleu Ngalagou, E Ngouadjeu Dongho Tsakeu, F Ngo Sack, E C Eboumbou Moukoko, Y Konn Jolly, H Luma
Data about malignant blood diseases are sparse in Cameroon. Their epidemiology was studied in patients at the General Hospital of Douala (GHD) and the Yaoundé Central Hospital (CHY) from 2004 through 2014. The variables we studied were social and demographic (age, sex, occupation, marital status), clinical (reasons for consultation, clinical signs, year of diagnosis), and biological (blood count, myelogram and blood smear, immunophenotyping, biopsy, and cytogenetics). In all, 4409 files were reviewed and 454 cases identified, documented and confirmed (248 in GHD and 206 in CHY)...
February 1, 2018: Médecine et Santé Tropicales
https://www.readbyqxmd.com/read/29605509/the-effects-of-lower-cd34-yields-after-lowe-dose-g-csf-induction-on-long-term-autologous-stem-cell-transplantation-outcome-a-single-center-study
#13
Mohammad Vaezi, Mohammad Shakouri, Maryam Souri, Mohammad Amin Setaredan, Seyed Asadollah Mossavi, Saeed Mohammadi, Kamran Alimoghaddam, Ardeshir Ghavamzadeh
Peripheral blood stem cell transplantation (PBSCT) is an effective treatment for hematological malignancies. Mobilization of peripheral blood stem cells performs in different ways among transplantation centers. Since the Effects of lower CD34+ cells dose after low dose G-CSF induction on autologous stem cell transplantation outcomes are not studied much, so this study was performed for this purpose. 735 autologous stem cell transplanted patients with diagnoses of multiple myeloma (n = 330), Hodgkin lymphoma (n = 200), non-Hodgkin lymphoma (n = 129), acute myeloid leukemia (n = 54) and solid tumors (n = 22) were retrospectively evaluated...
March 23, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29602958/hla-g-peptide-preferences-change-in-transformed-cells-impact-on-the-binding-motif
#14
Alexander A Celik, Gwendolin S Simper, Wiebke Hiemisch, Rainer Blasczyk, Christina Bade-Döding
HLA-G is known for its strictly restricted tissue distribution. HLA-G expression could be detected in immune privileged organs and many tumor entities such as leukemia, multiple myeloma, and non-Hodgkin and Hodgkin's lymphoma. This functional variability from mediation of immune tolerance to facilitation of tumor immune evasion strategies might translate to a differential NK cell inhibition between immune-privileged organs and tumor cells. The biophysical invariability of the HLA-G heavy chain and its contrary diversity in immunity implicates a strong influence of the bound peptides on the pHLA-G structure...
March 30, 2018: Immunogenetics
https://www.readbyqxmd.com/read/29597141/preliminary-evaluation-of-18-f-labeled-llp2a-trifluoroborate-conjugates-as-vla-4-%C3%AE-4-%C3%AE-1-integrin-specific-radiotracers-for-pet-imaging-of-melanoma
#15
Áron Roxin, Chengcheng Zhang, Sungjoon Huh, Mathieu L Lepage, Zhengxing Zhang, Kuo-Shyan Lin, François Bénard, David M Perrin
INTRODUCTION: The transmembrane α4 β1 integrin receptor, or very-late antigen 4 (VLA-4), is associated with tumor metastasis and angiogenesis, the development of chemotherapeutic drug resistance, and is overexpressed in multiple myelomas, osteosarcomas, lymphomas, leukemias, and melanomas. The peptidomimetic, LLP2A, is a high-affinity ligand with specificity for the extracellular portion of VLA-4 and several conjugates have been evaluated in vivo by NIR-fluorescence,111 In-SPECT and68 Ga- and64 Cu-PET imaging, but to date, not with18 F-PET...
March 12, 2018: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29589834/hierarchical-involvement-of-myeloid-derived-suppressor-cells-and-monocytes-expressing-latency-associated-peptide-in-plasma-cell-dyscrasias
#16
Tamar Tadmor, Ilana Levy, Zahava Vadasz
Plasma cell dyscrasias (PCD) are disorders of the plasma cells having in common the production of a monoclonal M-protein. They include a spectrum of conditions which may represent a natural progression of the same disease from monoclonal gammopathy of unknown significance (MGUS), to asymptomatic and symptomatic multiple myeloma and plasma cell leukemia and Waldenström's macroglobulinemia (WM). In PCD the immune system is actively suppressed through the secretion of suppressive factors and the recruitment of immune suppressive subpopulations...
March 28, 2018: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
https://www.readbyqxmd.com/read/29589466/a-systematic-review-of-epidemiologic-studies-of-styrene-and-cancer
#17
James J Collins, Elizabeth Delzell
Previous epidemiology reviews of exposure to styrene and the risk of cancer considered studies published through 13 November 2013. Since then, additional relevant research has been published. No review has included meta-analyses. The current systematic review considered research published through June 2017; included meta-analyses of the relationship between any exposure to styrene and cancers identified as being of concern, including non-Hodgkin lymphoma (NHL), leukemia and cancers of the esophagus, pancreas, lung and kidney; and evaluated several other forms of cancer...
March 28, 2018: Critical Reviews in Toxicology
https://www.readbyqxmd.com/read/29568990/necrobiotic-xanthogranuloma-a-30-year-single-center-experience
#18
Talal Hilal, David J DiCaudo, Suzanne M Connolly, Craig B Reeder
To characterize the clinical features, associated disorders, and treatment of necrobiotic xanthogranuloma (NXG), a rare non-Langerhans cell histiocytosis, we conducted a retrospective review of pathologically confirmed NXG at Mayo Clinic Arizona from 1987 to June 2017. Data on clinical findings, laboratory findings, associated disorders, therapy, and response to therapy were extracted. Nineteen patients were identified. Mean age was 54 years (range, 17-84) with equal gender distribution. Median follow-up was 5...
March 22, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29561206/venous-thromboembolism-in-patients-with-non-hodgkin-lymphoma-or-chronic-lymphocytic-leukemia-treated-with-lenalidomide-a-systematic-review
#19
Marc Sorigue, Elisa Orna, Juan-Manuel Sancho
Lenalidomide has been associated with an increased risk of venous thromboembolism (VTE) in multiple myeloma. It is unclear whether patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are also at such risk. We conducted a systematic review of the incidence of VTE in prospective trials of lenalidomide-treated patients with NHL or CLL. Sixty-eight unique reports were assessed for inclusion. For grade ≥3 VTE, 98 events were reported in 3043 patients (60 studies) (crude incidence: 3...
March 21, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29556955/adult-stem-cells-and-medicine
#20
Sinem Civriz Bozdağ, Meltem Kurt Yüksel, Taner Demirer
Stem cells can be either totipotent, pluripotent, multipotent or unipotent. Totipotent cells have the capability to produce all cell types of the developing organism, including both embryonic and extraembryonic tissues. The Hematopoietic Stem Cells (HSC) are the first defined adult stem cells (ASC) that give rise to all blood cells and immune system. Use of HSCs for treatment of hematologic malignancies, which is also called bone marrow (BM) transplantation or peripheral blood stem cells (PBSC) transplantation is the pioneer of cellular therapy and translational research...
March 20, 2018: Advances in Experimental Medicine and Biology
keyword
keyword
68335
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"